The Myriad Genetics Case: The Fight Over Who Owns Your Genes

LEGAL DISCLAIMER: This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation.

Imagine a mapmaker discovers a new, hidden island in the middle of the ocean. They meticulously chart its coastline, rivers, and mountains. Can they then claim to *own* the island itself and forbid anyone else from even visiting or talking about it? This is the central question behind the Myriad Genetics case. For decades, a company named Myriad Genetics held patents on two human genes, BRCA1 and BRCA2, which are strongly linked to hereditary breast and ovarian cancer. They didn't invent the genes—they exist inside our bodies—but they were the first to isolate them from the surrounding dna and identify their significance. This “ownership” allowed them to be the sole provider of tests for these genes in the U.S., charging thousands of dollars and controlling all research. This led to a monumental legal battle that reached the supreme_court_of_the_united_states, forcing the nation to ask a profound question: Can a part of the human body be a patentable invention?

• Key Takeaways At-a-Glance:
  • Natural DNA Cannot Be Patented: The Supreme Court's unanimous decision in the Myriad Genetics case established that naturally occurring human genes, even when isolated from the body, are “products of nature” and therefore cannot be patented under U.S. patent_law.
  • Synthetic DNA Can Be Patented: The ruling directly impacted patients and researchers by invalidating Myriad's core patents, which immediately allowed other labs to offer more affordable and comprehensive genetic tests, fostering competition and innovation in medical diagnostics.
  • A Clear Line Was Drawn: The Court did, however, rule that a synthetic form of DNA called complementary DNA (cDNA) can be patented because it is created in a lab and does not exist in nature, providing a path forward for biotechnology companies to protect their true inventions.

To understand the legal fight, we first need to understand the science. Inside almost every cell in your body is a complete copy of your DNA, your personal genetic blueprint. This blueprint is organized into sections called genes.

• Genes as Instructions: Think of a gene as a single recipe in a massive cookbook. Each recipe provides the instructions for building a specific protein, and proteins are the workhorses that do almost everything in your body.
• The BRCA “Guardian” Genes: The BRCA1 and BRCA2 genes (short for BReast CAncer genes 1 and 2) are crucial recipes for proteins that act like cellular mechanics. Their job is to repair damaged DNA and suppress tumor growth. They are “guardian” genes, helping to prevent cells from becoming cancerous.
• Harmful Mutations: Sometimes, there's a “typo” in the recipe—a genetic mutation. Certain mutations in the BRCA1 and BRCA2 genes prevent the guardian proteins from working correctly. This broken repair system dramatically increases a person's risk of developing hereditary breast, ovarian, prostate, and pancreatic cancers.

In the 1990s, scientists at the University of Utah, in collaboration with Myriad Genetics, won the intense international race to pinpoint the exact location and sequence of the BRCA1 and BRCA2 genes. This was a monumental scientific achievement. But what they did next turned science into a legal firestorm: they filed for patents.

The U.S. patent system is designed to promote innovation. It grants inventors an exclusive, temporary monopoly on their invention in exchange for them publicly disclosing how it works. This encourages people to invest time and money in research and development. The core law governing what can be patented is found in 35_u.s.c._101. It states that anyone who “invents or discovers any new and useful process, machine, manufacture, or composition of matter” may obtain a patent. However, the courts have long carved out three major exceptions to this rule. You cannot patent:

• Laws of nature (like gravity or E=mc²)
• Natural phenomena (a new mineral found in the earth, a new plant discovered in the Amazon)
• Abstract ideas (mathematical formulas)

Myriad Genetics argued that by “isolating” the BRCA genes—separating them from the rest of the DNA strand—they had created something new and distinct from what exists in the body. They claimed this isolated DNA was a “composition of matter” that did not exist in nature and was therefore patentable. For years, the U.S. Patent and Trademark Office (uspto) agreed with them, granting thousands of patents on human genes.

Myriad's patents on the BRCA genes gave them a complete monopoly in the United States for over 15 years. If you wanted to be tested for these critical mutations, you had to go through them. The consequences were profound:

• High Costs: The test cost upwards of $3,000, creating a significant financial barrier for many at-risk families.
• No Second Opinions: If a patient received an ambiguous result, they could not get their sample tested by another lab to confirm the findings.
• Stifled Research: Myriad's patents prevented other scientists from freely studying the BRCA genes. Researchers who wanted to develop better, faster, or cheaper tests were blocked by the patents and often received cease-and-desist letters.
• Ethical Outrage: Most powerfully, there was a widespread sense of unease. Patients, doctors, and civil liberties groups like the ACLU felt it was fundamentally wrong for a for-profit company to own a piece of the human genome—something that belongs to all of humanity.

This growing frustration and anger set the stage for a legal challenge that would redefine the boundaries of science, ethics, and law.

In 2009, the ACLU and the Public Patent Foundation filed a lawsuit on behalf of researchers, genetic counselors, patients, and medical associations against Myriad Genetics. The case, *association_for_molecular_pathology_v_myriad_genetics*, worked its way through the courts for years, culminating in a historic, unanimous decision by the Supreme Court in 2013.

The entire case hinged on a single, critical question: Is isolating a gene from its natural place in the human body enough to make it a patentable human invention?

• Myriad's Argument: Myriad's lawyers argued that isolated DNA is chemically different from DNA inside the cell. When scientists snip the gene out, they break chemical bonds, creating a new molecule that doesn't exist in nature. They compared it to a chemist isolating pure, useful lithium from a rock. The lithium was in the rock, but it wasn't in a usable form until the chemist's inventive work.
• The Challengers' Argument (ACLU et al.): The ACLU argued that this was a meaningless distinction. Myriad didn't invent the gene; they just found it. The genetic information—the sequence of As, Ts, Cs, and Gs that is the truly important part—is identical to what's in the body. They argued that patenting the gene was like patenting a kidney after removing it from the body or patenting a tree's leaves after plucking them from a branch. The location had changed, but the fundamental product of nature had not.

The Supreme Court cleverly split the difference, creating a clear and lasting distinction that guides the biotechnology industry to this day. The court looked at two different things Myriad had patented: isolated DNA and complementary DNA (cDNA).

This nuanced decision was a masterstroke. It accomplished two goals simultaneously: it freed the human genome for research and competition, while still protecting the investments of biotech companies that create genuinely new, lab-made genetic tools.

• The Plaintiffs (The Challengers): The lead plaintiff was the Association for Molecular Pathology (AMP), representing a coalition of over 150,000 scientists and lab professionals. They were joined by individual researchers, genetic counselors, women's health groups, and several cancer patients. The legal powerhouse driving the case was the ACLU, which saw the issue as a fundamental matter of civil liberties and public health.
• The Defendant (The Patent Holder): Myriad Genetics, Inc. was the company that held the patents on the BRCA1 and BRCA2 genes. They argued that their patents were essential to recoup the massive investment they had made in discovering the genes and developing the first diagnostic test.
• The U.S. Government: In a surprising move, the government's position evolved during the case. Initially, the uspto granted gene patents. But by the time the case reached the Supreme Court, the office of the solicitor_general argued on behalf of the government that isolated DNA should not be patentable, while cDNA should be—the exact position the Court ultimately adopted.

The Supreme Court's ruling wasn't just an abstract legal debate; it had immediate and dramatic effects on patients, doctors, and scientists across the country.

The impact for patients was a clear and overwhelming victory.

• Competition and Lower Prices: Within hours of the decision, other labs announced they would begin offering BRCA testing. This new competition caused prices to plummet from over $3,000 to, in some cases, just a few hundred dollars, making life-saving testing accessible to millions more people.
• More Comprehensive Tests: Myriad's test only looked at the BRCA1 and BRCA2 genes. Competitors began offering multi-gene panels that could test for dozens of cancer-related genes at once for a similar or lower price, providing patients with a much more complete picture of their genetic risk.
• Innovation in Testing: The freedom to work with the BRCA genes spurred the development of new testing technologies, improving the speed and accuracy of results.

For the scientific community, the decision was like the fall of the Berlin Wall. Researchers who had been blocked by Myriad's patents for years were suddenly free to study the BRCA genes without fear of a lawsuit. This led to an explosion of research, deepening our understanding of how these genes work and their role in cancer. It affirmed the principle that the basic building blocks of nature should be open to all for study and exploration.

While the biotech industry initially feared the decision would destroy investment, it ultimately provided clarity. The ruling established a new “playbook”:

• Focus on Application, Not Discovery: Companies learned they could no longer patent the raw genetic sequence they discovered. Instead, they had to focus their patent strategy on what they *invented* with that information—new diagnostic methods, gene therapies, unique applications of cDNA, or novel lab-created molecules.
• Protecting True Invention: The ruling protected patents on truly inventive work like creating cDNA or developing new genetic engineering technologies like crispr. This ensured that companies could still protect their most significant R&D investments.
• Clarity for Investors: The clear line drawn by the Court provided legal certainty, allowing investors and companies to make more informed decisions about which projects were commercially viable and legally defensible.

The *Myriad* decision did not happen in a vacuum. It was the culmination of a decades-long conversation in the courts about how patent law should apply to the life sciences.

• Backstory: Ananda Chakrabarty, a genetic engineer for General Electric, developed a bacterium capable of breaking down crude oil, which he proposed to use in cleaning up oil spills. The uspto rejected his patent application, arguing that living things were not patentable.
• Legal Question: Can a living, man-made microorganism be patented?
• The Holding: In a 5-4 decision, the Supreme Court said yes. The Court famously stated that “anything under the sun that is made by man” is patentable. Chakrabarty's bacterium was not a “natural phenomenon” but a product of human ingenuity with different characteristics from any found in nature.
• Impact on Myriad: This case opened the floodgates for patenting biotechnology. It was the foundational ruling that encouraged the uspto to begin granting patents on everything from cell lines to, eventually, isolated human genes, setting the stage for Myriad's patents.

• Backstory: Prometheus patented a method for doctors to optimize the dosage of certain drugs. The method involved administering the drug and then measuring the level of a metabolite in the patient's blood, with the patent claiming the specific metabolite levels that were considered safe or toxic.
• Legal Question: Can you patent a method that essentially just describes a natural law or relationship?
• The Holding: The Supreme Court unanimously said no. The Court found that the process Prometheus patented was just an instruction to doctors to observe a natural law (the relationship between the drug and metabolite levels) and then think about it. It lacked a sufficient “inventive concept.”
• Impact on Myriad: Decided just one year before *Myriad*, the *Mayo* decision signaled the Court's growing skepticism toward patents that seemed to monopolize basic scientific principles. It established a stricter framework for analyzing “product of nature” claims and heavily influenced the Court's reasoning in the *Myriad* case.

• Backstory: Alice Corp. held patents on a computerized system that acted as a third-party intermediary to mitigate financial settlement risk—a fundamental economic practice.
• Legal Question: Can you make an unpatentable abstract idea patentable simply by implementing it on a generic computer?
• The Holding: The Supreme Court unanimously said no. The Court found that the patent was just for an “abstract idea” and that using a computer to do the work did not add a sufficient “inventive concept” to make it patentable.
• Impact on Myriad: Decided after *Myriad*, the *Alice* case continued the trend of tightening patent eligibility. Together, *Mayo*, *Myriad*, and *Alice* form a trilogy of Supreme Court cases that have significantly narrowed what can be patented in the U.S., forcing inventors to demonstrate a greater degree of ingenuity beyond just observing nature or applying abstract concepts.

The *Myriad* decision settled the question of naturally occurring DNA, but the fast-moving world of biotechnology continues to raise new and complex legal challenges.

The spirit of the *Myriad* case lives on in today's most cutting-edge legal debates.

• CRISPR Gene Editing: The revolutionary CRISPR-Cas9 gene-editing technology has been the subject of a fierce, multi-year patent battle between the University of California and the Broad Institute of MIT and Harvard. The fight isn't over the discovery of CRISPR in nature, but over who first invented its application in more complex (eukaryotic) cells—a distinction that fits squarely within the *Myriad* framework of patenting applications, not natural phenomena.
• mRNA Vaccines: The technology behind the COVID-19 mRNA vaccines relies on using synthetic genetic material (mRNA) to instruct cells to create proteins. Companies like Moderna and Pfizer/BioNTech hold numerous patents, not on the coronavirus's natural genetic sequence, but on the inventive delivery mechanisms and modifications to the synthetic mRNA that make the vaccines work.
• Diagnostic Methods: The *Mayo* and *Myriad* rulings have made it much harder to patent diagnostic methods that rely on observing a correlation in the body. This remains a contentious area, with some arguing the current rules stifle investment in new, life-saving diagnostics.

The next wave of legal questions will likely come from the intersection of biology and artificial intelligence.

• AI-Discovered Genes and Proteins: What happens when an AI, not a human, analyzes a massive genetic dataset and discovers a new gene-disease correlation or designs a novel protein? Can an AI be an “inventor” under U.S. patent law? The uspto has so far said no, but this will be an area of intense future debate.
• Personalized Medicine: As medicine becomes increasingly tailored to an individual's unique genetic makeup, companies will develop complex algorithms to predict health outcomes. Are these algorithms unpatentable “abstract ideas” or patentable “inventive applications”? The courts will have to apply the principles from *Myriad* and *Alice* to this new technological landscape.

The legacy of the Myriad Genetics case is that it drew a bright line in the sand, reserving the raw code of nature for all, while still rewarding the ingenuity of those who build something new from it. It's a principle that will continue to guide American innovation for decades to come.

• 35_u.s.c._101: The section of the U.S. Code that defines what subject matter is eligible for a patent.
• ACLU: A non-profit organization that works to defend the individual rights and liberties guaranteed by the Constitution.
• association_for_molecular_pathology_v_myriad_genetics: The full legal name of the landmark Supreme Court case discussed in this article.
• brca1_brca2: Two genes that produce tumor-suppressing proteins; mutations in these genes are linked to a higher risk of hereditary cancers.
• cdna: Complementary DNA; a synthetic form of DNA created in a lab from an mRNA template, which is considered patent-eligible.
• crispr: A family of DNA sequences found in prokaryotes that is now a revolutionary gene-editing technology.
• dna: Deoxyribonucleic acid; the molecule carrying the genetic instructions for the development and function of all known living organisms.
• gene_patent: A patent on a specific gene sequence and its chemical composition.
• intellectual_property: A category of property that includes intangible creations of the human intellect, such as patents, copyrights, and trademarks.
• monopoly: The exclusive possession or control of the supply of or trade in a commodity or service.
• patent_law: The body of law that governs the creation, protection, and enforcement of patents.
• product_of_nature_doctrine: A legal principle that states that phenomena of nature, in their natural state, are not patentable.
• solicitor_general: The lawyer who represents the federal government before the Supreme Court of the United States.
• supreme_court_of_the_united_states: The highest court in the federal judiciary of the United States.
• uspto: The United States Patent and Trademark Office; the federal agency responsible for issuing patents.

• patent_law
• intellectual_property
• supreme_court_of_the_united_states
• diamond_v_chakrabarty
• mayo_v_prometheus
• alice_v_cls_bank
• 35_u.s.c._101